Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3465-3472

  Yiu, Christopher C P ^a,b,c,d   Chanplakorn, Niramol ^a,e   Chan, Monica S M ^a,b,d   Loo, Wings T Y ^a,b,c   Chow, Louis W C ^a,b,c,d   Toi, Masakazu ^f   Hironobu, Sasano ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Unimed Medical Institute   (Hong Kong)

^c Organization of Oncology Translational Research   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e MAHIDOL UNIVERSITY   (Thailand)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

Aromatase inhibitor; Breast cancer; Heat shock protein 70; Ki 67; Neoadjuvant

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; HEAT SHOCK PROTEIN 70; KI 67 ANTIGEN; LETROZOLE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; ADJUVANT THERAPY; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOADJUVANT THERAPY; NITRILES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZOLES;

EID: 77958596589     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Nabholtz JM, Buzda A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A and von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advance breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22): 3758-3767, 2000.
2. Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA and Lang R: Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroup and a test of functional ability. Oncologist 9(5): 489-496, 2004. (Pubitemid 39332312)
3. Paridaens RJ, Dirix LY, Beex LV, Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J and Therasse P: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organization for Research and Treatment of Breast Cancer Cooperative Group. J Clin Oncol 26(30): 4883-4890, 2008.
4. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG and Sahmoud T: ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359(9324): 2131-2139. Erratum in: Lancet 360(9344): 1520, 2002.
5. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ and Goss PE: Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 19(5): 877-882, 2008.
6. Rauscher GH, Ferrans CE, Kaiser K, Campbell RT, Calhoun EE and Warnecke RB: Misconceptions about breast lumps and delayed medical presentation in urban breast cancer patients. Cancer Epidemiol Biomarkers Prev 19(3): 640-647, 2010.
7. Mathis KL, Hoskin TL, Boughey JC, Crownhart BS, Brandt KR, Vachon CM, Grant CS and Degnim AC: Palpable presentation of breast cancer persists in the era of screening mammography. J Am Coll Surg 210(3): 314-318, 2010.
8. Hennequin C, Espié M, Misset JL and Maylin C: Does primary chemotherapy really increase the rate of breast-conserving treatments? Cancer Radiother 8(1): 48-53, 2004.
9. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M and Walsh G: IMPACT Trialists Group. Prognostic value of Ki-67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99(2): 167-170, 2007.
10. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB and Dixon JM: Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 27: 1382-1387, 2009.
11. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB and Dowsett M: Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 9(3): R37, 2007
12. Yiu CC, Sasano H, Ono K and Chow LW: Changes in protein expressions after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance. Expert Opin Investig Drugs 19(S1): S79-89, 2010.
13. Chow LW, Yip AY, Loo WT, Lam CK and Toi M: Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 111(1-2): 13-17, 2008
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3): 205-216, 2000. (Pubitemid 30099779)
15. Liu S, Edgerton SM, Moore DH II and Thor AD: Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7: 1716-1723, 2001. (Pubitemid 32708640)
16. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V and Horsfall DJ: Relationship between p53 gene abnormalities and other tumor characteristics in breast-cancer prognosis. Int J Cancer 69: 135-141, 1996.
17. Billgren AM, Tani E, Liedberg A, Skoog L and Rutqvist LE: Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer. Breast Cancer Res Treat 71: 161-170, 2002.
18. Brown RW, Allred CD, Clark GM, Osborne CK and Hilsenbeck SG: Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2: 585-592, 1996.
19. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of ERBB2 and ERBB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study. Clin Cancer Res 9: 923-930.
20. Haerslev T, Jacobsen GK and Zedeler K: Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 37: 101-113, 1996. (Pubitemid 26030089)
21. Thor AD, Liu S, Moore DH 2nd and Edgerton SM: Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17: 470-477, 1999.
22. Iacopetta B, Grieu F, Powell B, Soong R, McCaul K and Seshadri R: Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res 4: 1597-1602, 1998.
23. Rudolph P, Alm P, Heidebrecht HJ, Bolte H, Ratjen V, Baldetorp B, Fernö M, Olsson H and Parwaresch R: Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst 91: 271-278, 1999.
24. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, Nortilli R, Pelosi G and Cetto GL: Ki-67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis. Breast Cancer Res Treat 74: 433-437, 1994.
25. Rudolph P, Kühling H, Alm P, Fernö M, Baldetorp B, Olsson H and Parwaresch R: Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 105: 674-680, 2003.
26. Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Fernö M, Baldetorp B and Parwaresch R: Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol 32: 311-319, 2001. (Pubitemid 32246806)
27. Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K and Nordling S: Ki-67, p53, ER-receptors, ploidy and S-phase as prognostic factors in T1 node-negative breast cancer. Acta Oncol 36: 369-374, 1997.
28. Weikel W, Beck T, Mitze M and Knapstein PG: Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149-154, 1991.
29. Weikel W, Brumm C, Wilkens C, Beck T and Knapstein PG: Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev 19: 446-450, 1995.
30. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M and Gusterson BA: International Breast Cancer Study Group. Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors a surrogate marker? Cancer 97: 1321-1331, 2003.
31. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L and van de Vijver MJ: The utility of mitotic index, estrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 25: 356-363, 1999.
32. Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa AP, Calderini P and Liscia DS: Cell proliferation of breast cancer evaluated by antiBrdU and anti-Ki-67 antibodies: Its prognostic value on short-term recurrences. Eur J Cancer 29A: 1509-1513, 1993.
33. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR and Dowsett M: Reduced apoptosis and proliferation and increased BCL-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48(2): 107-116, 1998.
34. Miller WR, White S, Dixon JM, Murray J, Renshaw L and Anderson TJ: Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 94(7): 1051-1056, 2006.
35. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M and Sasano H: Increased estrogen sulfatase (STS) and 17beta-hydroxysteriod dehydrogenase type 1 (17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 20(3): 639-648, 2010.
36. Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A and Dixon JM: Aromatase inhibitors: cellular and molecular effects. J Steroid Biochem Mol Bio 95: 83-89, 2005.
37. Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM and Hwang ES: Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer 9: 285, 2009.
38. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W and Dowsett M: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100(19): 1380-1388, 2008.
39. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G and Smith IE: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or combination: influence of hormonal status and Her-2 in breast cancer- A study from the IMPACT Trialists. J Clin Oncol 23(11): 2477-2492, 2005.
40. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y and Iwase H: Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100(11): 2028-2033, 2009.
41. Miller WR, Dixon JM, Macfarlane L, Cameron D and Anderson TJ: Pathological features of breast cancer response following neoadjuvant treatment with either letrozole and tamoxifen. Eur J Cancer 39: 462-468, 2003.
42. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A and Perrone F: NCI-Naple Breast Cancer Group. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine Related Cancer 12(4): 721-747, 2005.
43. Johnston D, Oppermann H, Jackson J and Levinson W: Induction of four proteins in chick embryo cells arsenite. J Biol Chem 255: 6975-6980, 1980. (Pubitemid 11234439)
44. Voos W: A new connection: Chaperones meet a mitochondrial receptor. Mol Cell 11: 1-3, 2003.
45. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G: Heat-shock proteins 27 and 70. Anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5(22): 2592-2601, 2006.
46. Thanner F, Sütterlin MW, Kapp M, Rieger L, Kristen P, Dietl J, Gassel AM and Müller T: Heat-shock protein 70 as a prognostic marker in node-negative breast cancer. Anticancer Res 23(2A): 1057-1062, 2003.
47. Koshiyama M, Konishi I, Nanbu K, Nanbu Y, Mandai M, Komatsu T, Yamamoto S, Mori T and Fujii S: Immunohistochemical localization of heat-shock proteins HSP70 and HSP90 in the human endometrium: correlation with sex steroid receptors and Ki-67 antigen expression. J Clin Endocrinol Metab 80(4): 1106-1112, 1995.
48. Gurbuxani S, Schmitt E, Cande C, Parcellier A, Hammann A, Daugas E, Kouranti I, Spahr C, Pance A, Kroemer G and Garrido C: Heat-shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene 22: 6669-6678, 2003.
49. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jäättelä M: Selective depletion of heat-shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci USA 97: 7871-7876, 2000.
50. Zhao ZG and Shen WL: Heat-shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901. World J Gastroenterol 11: 73-78, 2005.
51. Schmitt E, Maingret L, Puig PE, Rerole AL, Ghiringhelli F, Hammann A, Solary E, Kroemer G and Garrido C: Heat-shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res 66: 4191-4197, 2006.
52. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D and Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270(5241): 1491-1494, 1995.
53. Koren J 3rd, Jinwal UK, Jin Y, O'Leary J, Jones JR, Johnson AG, Blair LJ, Abisambra JF, Chang L, Miyata Y, Cheng AM, Guo J, Cheng JQ, Gestwicki JE, Dickey CA: Facilitating Akt clearance via manipulation of Hsp70 activity and levels. J Biol Chem 285(4): 2498-2505, 2010.